tbuckley/cabot-search huggingface dataset:
Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma.
Authors: Haifeng Lin, Jie Ma, Manyun Zhuo, Chengsheng Zhang, Jingru Luo, Xiaohong Zhuang, Zhiming Zeng, Lihua Yang
Journal: Journal of Clinical Oncology (2021)

e16130 Background: The combination therapy of anti-angiogenic with anti-PD-1 /L1 agents has represented superior efficacy over sorafenib in the first-line treatment for unresectable HCC (uHCC). There are unmet medical needs due to limited options. Anlotinib is a novel oral multi-targeted tyrosine kinase inhibitor for tumor angiogenesis and proliferation, and has been approved for treatment of several malignancies in China. Toripalimab is a humanized IgG4 mAb against PD-1. Now we present the updated results with more patients enrolled and longer follow-up of ALTER-H003 to evaluate the efficacy and safety of anlotinib plus toripalimab as the first-line regimen for uHCC. Methods: This was a single-arm, multicenter, phase II trial. 30 patients (pts) with uHCC, previously untreated, Child-Pugh ≤7 and ECOG PS &lt;2 will be enrolled. Pts received anlotinib (12 mg, p.o., qd, d1-14, q3w) and toripalimab (240 mg, iv, d1, q3w) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) assessed by investigator according to mRECIST and irRECIST. Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DoR) and safety. Results: By the cutoff date of January 21, 2021, 18 pts were enrolled and durations of treatment ranged from 0.1+ to 7.4+ months, 13 pts were still on treatment. 14 pts were evaluable, confirmed ORR and DCR was 21.4% (95% CI 4.7%-50.8%) and 92.9% (95% CI 66.1%-99.8%) respectively according to mRECIST. one patient achieved a complete response (CR), and one additional patient remained on treatment with unconfirmed PR. The median duration of response (DoR) has not been reached and DoRs ranges from 2.4m to 4.9m. 14 of 18 pts (77.8%) experienced treatment-related adverse events (TRAEs), Grade 3 TRAEs occurred in 7 pts (38.9%). Immune-Related TRAEs (irTRAEs) occurred in 10 pts (55.6%), few grade 3 irTRAEs were observed. No grade 4 or higher (ir)TRAEs occurred. More detailed (ir)TRAEs information were shown in Table. Conclusions: Anlotinib in combination with toripalimab showed promising anti-tumor efficacy and manageable toxicity in the first-line treatment for uHCC patients. This study is still ongoing and more data is being updated. Most common (ir)TRAEs in enrolled pts (n=18). Clinical trial information: ChiCTR1900028295. [Table: see text]
Research brief
Authors: Jane Bradbury
Journal: The Lancet Infectious Diseases (2014)

The ability of HIV to enter a latent state is a major barrier to finding a cure for HIV/AIDS. Researchers now report that compounds that induce the stochastic fluctuations ("noise") in gene expression around the mean expression level that often drives cell-fate decisions could help to reactivate latent HIV. In a screen of bioactive small molecules, the researchers identified more than 80 compounds that modulated HIV gene-expression noise without changing mean expression. Notably, these noise-modulating compounds synergised with known transcriptional activators to reactivate HIV in latently infected human cells.
A Treatment Advance for Patients With Posttransplant CMV
Authors: Rebecca Voelker
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
1981: a milestone for heart-lung transplants
Authors: P. Gunby
Journal: JAMA (1981)

Four human heart-lung transplants have been performed this year at Stanford University Medical Center, Palo Alto, Calif—one more than in all the previous history of this procedure. Three of the four patients are still alive. The other three such operations were carried out in the late 1960s and early 1970s (although development of the surgical techniques and early animal studies associated with heart-lung transplants date back to the 1940s and 1950s) and did not enjoy the same success. The first recipient apparently was a 2 1/2-month-old girl who was admitted to Texas Children's Hospital, Houston, with an atrioventricular canal defect and pulmonary hypertension. Because the infant's condition was considered to be nearly terminal, on Sept 15, 1968, Denton A. Cooley, MD, and colleagues transplanted into the infant the heart and lungs of a day-old anencephalic infant who was being maintained on a ventilator. The recipient infant "died from pulmonary insufficiency
Muyocopron laterale: invasive human infection of a plant pathogen in an immunocompromised host
Authors: Priscillia Lye, Janet Cheng, Lionel Lum, Kean Lee Chew, Jeanette Teo, Ka Lip Chew
Journal: Clinical Microbiology and Infection (2022)

A 74-year-old Chinese man with a history of pure red cell aplasia on long-term prednisolone and cyclosporin presented with swelling and purulent discharge from the dorsum of his right hand after a cut a month earlier. The patient is a retired gardener but continued to garden at his home. He underwent surgical debridement of his right hand, during which necrotic tissue and hemopurulent discharge extending from the second to fifth metacarpophalangeal joints to his wrist were seen. The same type of mould was cultured from initial wound swabs and all subsequent tissue debridement. The infection progressed to necrotizing fasciitis despite antifungal treatment, including an initial course of itraconazole followed by a combination of liposomal amphotericin B and voriconazole. The patient eventually required an emergent above-elbow amputation of the right upper limb due to ongoing septic shock with multiorgan failure, but he died of infection after a month in the intensive care unit.
Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with <i>PIK3CA</i> mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Authors: Jean L. Grem, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Maged F. Khalil, Shane O. Rogosin, John Stuart Salmon, Timothy Lewis Cannon, Gina N. Grantham, Susan Halabi, Richard L. Schilsky
Journal: Journal of Clinical Oncology (2022)

106 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of CRC pts with PIK3CA mutation treated with T are reported. Methods: Eligible pts had advanced CRC with PIK3CA mutation reported by a genomic test performed in a CLIA-certified, CAP-accredited site selected lab, no standard treatment options, measurable disease, ECOG performance status (PS) 0-2, and adequate organ function. Use of T was approved by the TAPUR Molecular Tumor Board in each case. After antihistamine pre-treatment, T was administered at 25 mg IV over 30-60 minutes weekly until disease progression. Primary endpoint was disease control (DC), defined as complete (CR) or partial (PR) response per RECIST v. 1.1, or stable disease at 16+ weeks (SD 16+). Simon 2-stage design tested the null DC rate of 15% vs. 35% (power = 0.85; α = 0.10). If ≥2 of 10 pts in stage 1 has DC, 18 more pts are enrolled; otherwise, the study stops for futility. If ≥7 of 28 pts has DC, the null DC rate is rejected. Secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. Results: 10 pts (60% male) with CRC with PIK3CA mutation were enrolled from November 2017 to May 2020. All were eligible for efficacy and toxicity. Demographics and outcomes are summarized in Table. No objective responses (OR) were observed. 1 pt had SD of 16.1 wks duration for a DC rate of 10% (95% CI: 0%, 45%); the null DC rate of 15% was not rejected (p=0.80). 6 pts had at least one grade 3-4 adverse or serious adverse event (AE/SAE) at least possibly related to T, including acute kidney injury, dehydration, decreased platelet count hypertriglyceridemia, mucositis, neutropenia, and scrotal and penile edema. Conclusions: Monotherapy T does not have sufficient clinical activity in CRC pts with PIK3CA mutation for continued evaluation in this pt population. Other treatments should be considered for these pts, including treatments offered in clinical trials. Clinical trial information: NCT02693535. [Table: see text]
Preliminary experience with circumferential mapping to guide isolation of the pulmonary veins in patients with atrial fibrillation Andrea Natale, Walid Saliba, Christopher Cole, Stephen Pavia, Cathy Lam, Mark Niebauer, Mina K. Chung, Alejandro Perez-Lugones, Thomas Dresing, Patrick Tchou, Robert Schweikert. Cleveland Clinic Foundation, Cleveland
Journal: Journal of the American College of Cardiology (2001)
Questions and Answers
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 17276: Tissue Plasminogen Activator Loaded Microbubbles for the Treatment of Coronary Microvascular Obstruction
Authors: Stephen J D’Auria, Filip Istvanic, Francois Yu, Xucai Chen, John Pacella
Journal: Circulation (2018)

Introduction: Microvascular obstruction (MVO) occurs frequently during successful PCI for acute myocardial infarction. Our previous work has demonstrated the potential of using ultrasound targeted microbubbles (MBs) cavitation to relieve MVO, termed sonoreperfusion (SRP). Hypothesis: In the present study, we aim to develop a tPA loaded MB in order to utilize the thrombolytic effects of locally delivered tPA to enhance SRP, with a decreased tPA dose to limit the bleeding risk. Methods: tPA (1 mg/mL) was first modified via a maleimide linkage using BMCC-biotin, leading to a biotinylated protein. The biotinylated tPA (0.87 mg/mL) was then mixed with streptavidin labeled lipid shelled MB (1х10^9MB/mL) via biotin-streptavidin bridging. The enzymatic activity of the tPA in these tPA loaded MBs were was tested with whole porcine blood thrombus and with a tPA chromogenic activity kit. The loading capability of tPA onto the MBs was determined by BCA protein assay. The SRP efficacy of the loaded tPA MB was tested in an in vitro model of MVO and compared with full dose systemic tPA as well as modified MB. Results: tPA loaded MB showed successful lysis of whole porcine blood clot in vitro , as evidenced by decreased thrombus weight. Subsequent analysis of tPA activity showed that there was no significant difference in the activity of stock tPA when compared to the BMCC labeled tPA (42.0±3.4 IU vs 44.7±1.1 IU, p =0. 17). tPA was loaded onto MB at volumetric ratios of 3 units of tPA at 0.87 mg/mL to 1 unit (3:1) of MB at 1e9 MB/mL (43.5±2.2 IU, p =0.38) and 6:1 (39.3±1.5 IU, p =0.15). There was decreased activity in the 1:1 group. The loading capability of tPA for the 3:1 tPA loaded MB was 6.2e-7 μg per MB, with a loading efficiency of 10.4% of the stock tPA. Early in vitro work showed the tPA loaded MB to be non-inferior at relieving MVO with SRP when compared to infusion of full dose tPA and SRP with standard unmodified tPA. Conclusions: We successfully loaded tPA onto the surface of a lipid encapsulated MB, with retention of the enzymatic activity of tPA. The loading efficiency was 10.4% of the stock tPA. The tPA loaded MB demonstrated similar reperfusion efficacy to full systemic dose tPA. Thus, this approach of targeted local delivery of tPA may provide a means to mitigate bleeding risk without sacrificing drug efficacy.
Correction to Lancet Public Health 2019; published online April 24. https://doi.org/10.1016/S2468-2667(20)30099-2
Journal: The Lancet Public Health (2020)

In the table in this letter, the case fatality rate in the rest of Italy should have read 10•6% and the mortality in Lombardy should have been 112•9 per 100 000.The text should have read "As of April 15, Lombardy had 112•9 deaths per 100 000 population, almost six times higher than in the rest of Italy".
Nordisk Medicin, Stockholm
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dissimilar Control Interventions in Clinical Trials Undermine Interpretability—Reply
Authors: Yoni K. Ashar, Tor D. Wager
Journal: JAMA Psychiatry (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
RE: A synthetic peptide from transforming growth factor-β1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. <i>Cardiovascular Research</i>, Volume 81, Issue 3, 15 February 2009, Pages 601–609. Javier Díez, https://doi.org/10.1093/cvr/cvn315
Journal: Cardiovascular Research (2020)
BOOK REVIEWS
Authors: MATTHEW B. LUBIN
Journal: JNCI Journal of the National Cancer Institute (1991)

BOOK REVIEWS Familial Cancer. Hj. MÜller, W. Weber, eds. Basel: S. Karger, 1985. 292pp., illus. $78.75. MATTHEW B. LUBIN MATTHEW B. LUBIN Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 24, 18 December 1991, Page 1830, https://doi.org/10.1093/jnci/83.24.1830 Published: 18 December 1991
Twenty-Sixth Annual Report of the State Board of Health of Massachusetts.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editorial: Medicine in the Common Market.
Journal: BMJ (1973)

of steam or nebulized saline reduces its viscosity and is always worth a trial when a patient is having difficulty in clearing his bronchi of tenacious sputum.Exacerbations of bronchitis may be associated with re- versible airways obstruction, and if this is suspected a bronchodilator aerosol or a short course of an oral corticosteroid should be prescribed.If a patient with an exacerbation of chronic bronchitis develops central cyanosis and becomes drowsy, it should be assumed that these are manifestations of ventilatory failure, and he should be ad- mitted to hospital without delay.Treatment of this com- plication is not practicable in the home, since it demands continuous low-concentration oxygen therapy and in some cases artificial pulmonary ventilation.
Raman spectroscopy provides quantitative evaluation of the effects of anti-atherosclerotic drugs on plaque formation Sweder W. E. van de Poll, Dianne Delsing, Wouter Jukema, Arnoud van der Laarse, Gerwin J. Puppels. Leiden University Medical Center, Leiden, The Netherlands, Erasmus University Rotterdam, Rotterdam, The Netherlands
Journal: Journal of the American College of Cardiology (2001)
Abstract P074: Racial Differences in the Association Between Hemoglobin A1c and Hypoglycemic Events
Authors: Mary E Lacy, Rachel A Whitmer, Mark J Pletcher
Journal: Circulation (2018)

Background: Rates of severe hypoglycemia are higher in African Americans than in whites. We hypothesize that the elevated rate of hypoglycemic events observed in African Americans is a result of treating African Americans and whites to the same target hemoglobin A1c (hbA1c) despite established racial differences in the association between hbA1c and glucose measures. Methods: Using de-identified patient clinical data from 2011- 2017 on 22,554 self-identified African American or white patients with type 2 diabetes from UCSF Health, we examined racial differences in the association between hbA1c and hypoglycemic events. Results: Of the 22,554 patients (17% African American; 54% male; mean age 59.6), 275 experienced a hypoglycemic event requiring medical care; 2.20% of African Americans experienced a hypoglycemic event compared to 1.02% of whites (p&lt;0.001). Of the 275 patients experiencing a hypoglycemic event, 102 had a last recorded hbA1c value within 90 days prior to the event. The mean hbA1c value preceding a hypoglycemic event was 7.50% for African Americans compared to 6.91% in whites (mean difference= 0.59%, 95% confidence interval: -0.38%, 1.56%, p=0.24). In models adjusted for age, sex, and duration of diabetes, the difference in hbA1c was slightly attenuated (mean difference= 0.56%, 95%CI: -0.41%, 1.52%, p=0.26). Conclusion: In this population, African Americans were significantly more likely to experience a hypoglycemic event than whites. HbA1c values preceding the event were slightly higher in African Americans than whites; this finding was not statistically significant but statistical power was potentially limited by sample size.